Findings

What do systematic reviews say?

517 questions · 551 findings · 17 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 65 · 11.8%GRADE not reported 419 · 76%Very low 29 · 5.3%Low 25 · 4.5%Moderate 13 · 2.4%High 0 · 0%

Fluconazole (absorbed from GI tract) vs Ketoconazole (absorbed from GI tract)

Mycological: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Fluconazole (absorbed from GI tract) showed no clear difference in mycological: eradication of oral candidiasis compared with ketoconazole (absorbed from GI tract); GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.95 [0.52, 1.72]
1 study · 37 participants
GRADE not reported

Miconazole 50 mg tablet (partially absorbed) vs Miconazole 500 mg gel (partially absorbed)

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Miconazole 50 mg tablet (partially absorbed) showed no clear difference in clinical: eradication of oral candidiasis compared with miconazole 500 mg gel (partially absorbed); GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.16 [0.91, 1.47]
1 study · 282 participants
GRADE not reported

Fluconazole (absorbed from GI tract) vs Itraconazole

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Fluconazole (absorbed from GI tract) showed no clear difference in clinical: eradication of oral candidiasis compared with itraconazole (absorbed from GI tract); GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.14 [1.00, 1.30]
2 studies · 293 participants
GRADE not reported

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Cost of oral care · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found

Phenytoin mouthrinse vs placebo

Quality of life · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Phenytoin mouthrinse led to lower quality of life compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
7 days
MD -15.10 [-26.04, -4.16]
1 study · 12 participants
GRADE not reported

Diclofenac vs placebo

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Diclofenac showed no clear difference in average pain scores (0-100 VAS) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -0.30 [-0.86, 0.26]
1 study · 66 participants
GRADE not reported

Human placental extract vs Disprin (aspirin/betamethasone)

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Human placental extract led to higher improvement in mucositis compared with disprin (aspirin/betamethasone); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 4.50 [2.29, 8.86]
1 study · 120 participants
GRADE not reported

Relaxation and imagery training vs control (e.g. usual activities)

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Relaxation and imagery training showed no clear difference in average pain scores (0-100 VAS) compared with control (treatment as usual); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -8.22 [-21.79, 5.35]
1 study · 46 participants
GRADE not reported

'Magic' mouthwash (lidocaine, diphenhydramine, aluminium hydroxide) vs Salt and soda mouthwash

Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

'Magic' mouthwash (lidocaine, diphenhydramine, aluminium hydroxide) showed no clear difference in mucositis eradicated compared with salt and soda mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.98 [0.78, 1.24]
1 study · 133 participants
GRADE not reported

Gelclair vs Sucralfate and mucaine

Mucositis severity (mild to moderate) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Gelclair showed no clear difference in mucositis severity (mild to moderate) compared with sucralfate and mucaine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 0.50 [0.17, 1.46]
1 study · 20 participants
GRADE not reported

Absorbed drug (fluconazole or ketoconazole) vs Antifungal drugs not absorbed from GI tract

Mycological: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Absorbed drug (fluconazole or ketoconazole) led to higher mycological: eradication of oral candidiasis compared with drug not absorbed from GI tract (amphotericin B or nystatin); GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.82 [1.28, 2.57]
3 studies · 189 participants
GRADE not reported

Phenytoin mouthrinse vs placebo

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Phenytoin mouthrinse showed no clear difference in average pain scores (0-100 VAS) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -1.70 [-3.85, 0.45]
1 study · 12 participants
GRADE not reported

Absorbed drug (fluconazole or ketoconazole) vs Antifungal drugs not absorbed from GI tract

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Absorbed drug (fluconazole or ketoconazole) led to higher clinical: eradication of oral candidiasis compared with drug not absorbed from GI tract (amphotericin B or nystatin); GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 1.29 [1.09, 1.52]
3 studies · 207 participants
GRADE not reported

Vitamin E (topical) vs vitamin E

Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Vitamin E (topical) led to higher improvement in mucositis compared with vitamin E (swallowed); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
5 days
RR 15.40 [4.01, 59.21]
1 study · 63 participants
GRADE not reported

Morphine via pharmacokinetically based PCA (PKPCA) vs Morphine via patient-controlled analgesia (PCA)

Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Morphine via pharmacokinetically based PCA (PKPCA) led to higher daily mean opiate intake per hour compared with morphine via patient-controlled analgesia (PCA); GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD 3.60 [1.47, 5.73]
1 study · 35 participants
GRADE not reported

Clotrimazole (partially absorbed from GI tract) vs placebo

Mycological: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Clotrimazole (partially absorbed from GI tract) showed no clear difference in mycological: eradication of oral candidiasis compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
RR 6.13 [0.38, 99.14]
1 study · 13 participants
GRADE not reported

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found

Patient-controlled analgesia (PCA) pethidine vs Staff-controlled delivery of pethidine

Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis

Patient-controlled analgesia (PCA) pethidine showed no clear difference in average pain scores (0-100 VAS) compared with staff-controlled delivery of pethidine; GRADE not reported.

1 finding from 1 review

Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
MD -21.00 [-45.79, 3.79]
1 study · 20 participants
GRADE not reported

Partially absorbed antifungal drug (e.g., clotrimazole, miconazole) vs Drug not absorbed from GI tract (e.g., nystatin, amphotericin B)

Outcome not reported · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
There were no trials comparing partially absorbed drugs with either absorbed drugs or drugs not absorbed.
0 studies
No studies found

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

Incidence of systemic infection · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found